Boston-based Atea Pharmaceuticals (Nasdaq: AVIR) reported positive topline results from its Phase III C-BEYOND trial on July 28, with the fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR) demonstrating statistical non-inferiority to Gilead Sciences' Epclusa (sofosbuvir/velpatasvir) in treatment-naïve adults with chronic hepatitis C virus infection. The result clears the most consequential hurdle in Atea's development program and positions the company to pursue regulatory submission.
In the modified intent-to-treat population of 905 patients, BEM/RZR achieved a 93.9% sustained virologic response rate versus 94.8% for sofosbuvir/velpatasvir, with the 95% confidence interval for the difference falling within the prespecified 5% non-inferiority margin. The result constitutes the primary FDA-agreed endpoint. Critically, patients without cirrhosis — approximately 80-90% of the real-world HCV population — received only 8 weeks of BEM/RZR versus the standard 12-week course of sofosbuvir/velpatasvir, with SVR rates of 93.5% and 94.6% respectively. In the cirrhotic subgroup, both arms achieved 95.4% SVR on identical 12-week regimens. No drug-related serious adverse events or drug-related early discontinuations were reported.
Bemnifosbuvir is a guanosine nucleotide analog prodrug that inhibits the HCV NS5B RNA-dependent RNA polymerase through chain termination of viral RNA synthesis; ruzasvir targets the NS5A replication complex protein, disrupting viral RNA replication and virion assembly across multiple genotypes.
The 8-week duration for non-cirrhotic patients is the commercial differentiator Atea has been building toward. AbbVie's Mavyret (glecaprevir/pibrentasvir) already offers an 8-week pan-genotypic regimen for treatment-naïve patients without cirrhosis, so BEM/RZR must compete on the strength of its drug-drug interaction profile. Atea's prior Phase I data, presented at EASL 2026, demonstrated that BEM/RZR can be co-administered with proton pump inhibitors and statins without clinically meaningful pharmacokinetic changes — a relevant advantage given that roughly 80% of HCV patients in the US take concomitant medications. Sofosbuvir/velpatasvir, the comparator here, carries label warnings around acid-reducing agents that complicate real-world prescribing.